Results 71 to 80 of about 577,308 (213)

Toward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints

Medicine Bulletin, Volume 2, Issue 4, Page 388-405, September 2026.
ABSTRACT Atherosclerosis remains the dominant substrate of atherosclerotic cardiovascular disease (ASCVD), yet recurrent events persist even when LDL cholesterol is driven to guideline targets, underscoring residual risk as a central limitation of contemporary prevention.
Yundong Peng, Rui Li, Huan Li, Jun Zhou, Xuanshi Liu, Guilherme Valente, Tataiana de Campos Melo, Sifan Chen, Lei Gu   +8 more
wiley   +1 more source

Identification of JAK2 exon 12 mutations in patients with polycythemia vera

Zdravniški Vestnik, 2012
Background: Polycythemia vera (PV) is characterized by erythrocytosis and mutation in JAK2 gene. More than 95 % of patients with PV have somatic mutation JAK2 V617F.
Marija Jedrt Mandelc Mazaj, Sašenka Lozar, Peter Černelč, Tadej Pajič   +3 more
doaj  

Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.

, 2008
International audienceOBJECTIVE: Previous studies have suggested that two subtypes of essential thrombocythemia (ET) could be separated on the basis of their JAK2 status (V617F-positive or V617F-negative), with a continuum between V617F-positive ET and ...
Bouamrani, Ali, Lippert, Eric, Vincent, Praloran, Arlotto, Marie, Berger, François, R., Hermouet, Sylvie, Girodon, François, Mossuz, Pascal, Dobo, Irène, Cahn, Jean-Yves   +9 more
core   +1 more source

JAK2 V617F Mutation Prevalence in Myeloproliferative Neoplasms in Pernambuco, Brazil [PDF]

, 2015
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Background: The JAK2 V617F mutation is associated with three myeloproliferative neoplasms (MPNs): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
de Albuquerque, DM, Hatzlhofer, BLD, Fertrin, KY, Lima, ASD, Machado, CGD, da Silva, RR, Costa, FF, Araujo, AD, Bezerra, MAC, dos Santos, MNN   +9 more
core   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, Volume 209, Issue 3, Page 988-997, September 2026.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source

Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Blood, 2007
To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients.
Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC   +9 more
openaire   +3 more sources

Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan

Genetics and Molecular Biology, 2008
A unique mutation of the JAK2 gene, V617F, has recently been identified in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis.
Naoki Mori, Kentaro Yoshinaga, Makiko Tada, Yanhua Wang, Masayuki Shiseki, Toshiko Motoji   +5 more
doaj   +1 more source

Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant. [PDF]

PLoS ONE, 2013
The acquired mutation (V617F) of Janus kinase 2 (JAK2) is observed in the majority of patients with myeloproliferative neoplasms (MPNs). In the screening of genes whose expression was induced by JAK2 (V617F), we found the significant induction of c-Myc ...
Megumi Funakoshi-Tago, Kazuya Sumi, Tadashi Kasahara, Kenji Tago   +3 more
doaj   +1 more source

Clonal Hematopoiesis in Colorectal Cancer: Mechanisms and Implications

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Clonal hematopoiesis (CH) arises from the expansion of hematopoietic stem and progenitor cells bearing somatic mutations, often in genes linked to epigenetic regulation and inflammation. Once considered a benign age‐related phenomenon, CH has gained increasing attention for its potential to influence cancer biology beyond hematologic ...
Chenyue Xia, Yi Lu, Jinhui Gu
wiley   +1 more source

Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. [PDF]

PLoS ONE, 2011
BACKGROUND: JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and kinase activation, has been incorporated into the WHO classification and diagnostic criteria of myeloid neoplasms.
Zhiyuan Wu, Hong Yuan, Xinju Zhang, Weiwei Liu, Jinhua Xu, Wei Zhang, Ming Guan   +6 more
doaj   +1 more source